Form 4: Arcutis Biotherapeutics CEO Sells 15,000 Shares Under 10b5-1 Plan
SEC Form 4 Filing
Arcutis Biotherapeutics CEO, Todd Franklin Watanabe, sold 15,000 shares of common stock at an average price of $15.1711, as part of a pre-arranged 10b5-1 trading plan.
Summary
- Todd Franklin Watanabe, CEO of Arcutis Biotherapeutics, sold 15,000 shares of common stock on December 20, 2024.
- The sale was executed under a 10b5-1 trading plan adopted on June 14, 2024, with an end date of September 30, 2025.
- The shares were sold at prices ranging from $15.00 to $15.73, with a weighted average price of $15.1711.
- Following the transaction, Watanabe directly owns 823,430 shares of Arcutis common stock.
- Watanabe also has indirect ownership of shares through various trusts and an LLC, totaling 230,137 shares.
- The report also corrects an error in a previous filing, adjusting the total shares owned to include acquisitions under the Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The document reflects a routine insider stock sale under a pre-arranged plan, which is neither particularly positive nor negative. The correction of a previous error is a neutral event.
Risks
- Sales by insiders, even under a 10b5-1 plan, can sometimes be perceived negatively by the market.
Future Outlook
The 10b5-1 trading plan is set to continue until September 30, 2025, suggesting further potential sales by the CEO.
Management Comments
- The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024 by the Reporting Person, with a plan end date of September 30, 2025.
Industry Context
Insider trading activity is closely monitored in the biotech industry, and this filing provides transparency into the CEO's transactions. It is common for executives to use 10b5-1 plans to manage their stock sales.
Comparison to Industry Standards
- 10b5-1 trading plans are a common practice among executives in publicly traded companies, including those in the biotech sector, such as Regeneron Pharmaceuticals (REGN) and Amgen (AMGN).
- These plans allow for scheduled sales to avoid accusations of insider trading based on non-public information.
- The reported sale is within the typical range of insider transactions for a company of Arcutis's size and stage.
Stakeholder Impact
- The stock sale may have a minor impact on shareholder sentiment, but it is unlikely to cause significant concern given the pre-planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date the 10b5-1 trading plan was adopted. |
| 05/31/2024 | Date of acquisition of 4,000 shares under the Employee Stock Purchase Plan. |
| 11/30/2024 | Date of acquisition of 2,038 shares under the Employee Stock Purchase Plan. |
| 12/03/2024 | Date of previous Form 4 filing that contained an error. |
| 12/20/2024 | Date of the reported stock sale. |
| 12/23/2024 | Date of the Form 4 filing. |
| 09/30/2025 | End date of the 10b5-1 trading plan. |
Keywords
Arcutis Biotherapeutics, Todd Franklin Watanabe, insider trading, 10b5-1 plan, stock sale, ARQT, CEO, share ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.